Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (NASDAQ: QDEL) is a global leader in diagnostic healthcare solutions, specializing in rapid testing technologies that inform critical clinical decisions. This news hub provides investors and healthcare professionals with timely updates on the company's innovations, regulatory milestones, and market developments.
Access official press releases and curated analysis covering financial results, product launches, strategic partnerships, and advancements in immunoassay or molecular diagnostic technologies. Our repository simplifies tracking of QDEL's contributions to transfusion safety, infectious disease detection, and clinical chemistry solutions across 100+ countries.
Bookmark this page for direct access to essential updates about FDA clearances, international expansion efforts, and research breakthroughs. All content is sourced from verified channels to ensure accuracy in reporting on this NASDAQ-listed innovator's role in shaping diagnostic medicine.
QuidelOrtho (Nasdaq: QDEL) has received FDA 510(k) clearance for its VITROS syphilis assay, now available on VITROS 3600, 5600, and XT 7600 systems in the U.S. This automated assay detects total antibodies to Treponema pallidum in human serum and plasma, aiding in syphilis diagnosis. The launch addresses the growing syphilis epidemic in the U.S., with over 176,000 new cases reported annually and a 36% increase in primary and secondary syphilis since 2021.
The VITROS syphilis assay improves laboratory efficiency by allowing labs to follow the CDC's reverse testing algorithm for syphilis screening. It also reduces costs through earlier disease detection, minimizing the need for external lab referrals. This expansion aims to provide timely and accurate diagnosis, important for effective treatment and disease control.
QuidelOrtho (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, has announced its participation in two upcoming investor conferences:
1. Morgan Stanley 22nd Annual Global Health Conference in New York, NY on September 5, 2024. President and CEO Brian Blaser and CFO Joseph Busky will participate in a fireside chat at 7:00 a.m. ET.
2. 2024 Baird Global Healthcare Conference in New York, NY on September 10, 2024. Blaser and Busky will participate in a fireside chat at 9:40 a.m. ET.
Live webcasts and replays of both events will be accessible through the 'Events & Presentations' section of QuidelOrtho's Investor Relations webpage.
QuidelOrtho (Nasdaq: QDEL) reported its Q2 2024 financial results. Key highlights include:
- Total revenue of $637 million, down from $665 million in Q2 2023
- GAAP diluted loss per share of ($2.20), compared to ($0.80) in Q2 2023
- Adjusted diluted loss per share of ($0.07), down from $0.26 in Q2 2023
- Adjusted EBITDA of $90 million with a 14% margin
The company announced $100 million in annualized cost-savings initiatives to benefit H2 2024 and H1 2025. QuidelOrtho is focusing on aligning operating expenses with revenue expectations and prioritizing R&D efforts in key growth areas.
QuidelOrtho (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, has announced that it will report its financial results for the second quarter of 2024 on Wednesday, July 31, 2024, after the market close. The company will hold a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results.
Interested parties can access the call through the 'Events & Presentations' section of QuidelOrtho's Investor Relations webpage. Presentation materials will be posted at the time of the call. Those unable to access the webcast can join via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) with Conference ID 533267. A replay of the call will be available on the company's website shortly after the event.
QuidelOrtho (Nasdaq: QDEL), a leader in in vitro diagnostic technologies, announced its management team's participation in the 44th Annual William Blair Growth Stock Conference. The event is scheduled for June 5, 2024, in Chicago, IL. The company's presentation will take place at 1:20 p.m. CT. Interested parties can access the live webcast and replay on QuidelOrtho's Investor Relations page.
QuidelOrtho (Nasdaq: QDEL) has launched a new state-of-the-art distribution center in Pedricktown, New Jersey, enhancing its U.S. distribution footprint. This strategic move aims to strengthen supply chain resilience and improve the customer experience. Partnering with a third-party logistics provider, QuidelOrtho aims to fulfill orders more efficiently. The company is also committed to sustainability, introducing greener, paper-based packaging that is recyclable. This initiative is expected to impact 15-20% of its domestic shipments over the coming months.
QuidelOrtho reported global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue. They are undergoing cost reduction initiatives to save approximately $100 million annually. The company suspended its 2024 financial guidance as they assess the business under a new President and CEO. Revenue for Q1 2024 was $711 million, with non-respiratory revenue flat at $574 million and respiratory revenue at $137 million, a 48% decrease due to lower COVID-19 revenue. The company appointed Brian J. Blaser as President and CEO effective May 6, 2024.
QuidelOrtho (Nasdaq: QDEL) appoints Brian J. Blaser as President and Chief Executive Officer, bringing over two decades of leadership experience in the In-Vitro Diagnostics Industry. The Board of Directors expands to eleven members, with Mr. Blaser joining on May 15, 2024. Known for his success in transformational strategies to drive revenue growth and profitability, Mr. Blaser's appointment is set to guide QuidelOrtho through its next phase of growth.
FAQ
What is the current stock price of Quidel (QDEL)?
What is the market cap of Quidel (QDEL)?
